NANJING, China, March 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 fourth quarter and full year results on Thursday, March 12, 2009, before the market opens in the United States. Simcere’s chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company’s 2008 fourth quarter and full year results on Thursday, March 12, at 8 a.m. ET (Thursday, March 12, at 8 p.m. Beijing/Hong Kong time).

Please ask to be connected to Simcere’s Q4 2008 earnings call and provide the following passcode: 77163710. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the “Investor Relations” section of the company’s web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

The passcode for replay participants is: 92927155. The telephone replay also will be archived on the “Investor Relations” section of the company’s web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

CONTACT: For investor and media inquiries, ir@simcere.com; In Nanjing:

Frank Zhigang Zhao, Chief Financial Officer of Simcere Pharmaceutical

Group, +86-25-8556-6666 x8818; or In Beijing: Kejia Wu, Brunswick Group, or

+86-10- 6566-2256; or In Hong Kong: Joseph Lo Chi-Lun of Brunswick Group,

+852-3512- 5000; or In New York: Michael Guerin of Brunswick Group LLC,

+1-212-333-3810

Web site: http://www.simcere.com/